TLR7 and allergic rhinitis: Another placebo‐controlled trial showed that repeated intranasal TLR7 agonist AZD8848 reduced symptoms in patients with birch and/or grass pollen allergic rhinitis, but it produced reversible blood lymphocyte reduction and dose‐dependent flu‐like symptoms as side‐effects 28.